Daily Dose - Jan 30th, 2026
Daily Dose |
View online
January 30, 2026
Lilly to invest $3.5B in injectable drug, device manufacturing facility in Pennsylvania
The Lehigh Valley site, Lilly’s fourth new U.S. build announced since February 2025, will produce its next-generation weight loss medicines.
Read More
US biomanufacturing investment sees 20% spike since 2024: report
It is the largest increase of the four major industries tracked by commercial real estate firm Newmark, which analysts contend is the start of a super-cycle for the sector.
Read More
Vetter plans €480M injectable drug manufacturing site in Germany
Construction of the Saarland facility is scheduled to begin in 2026, with operations expected to start in 2031.
Read More
WuXi Biologics, Sinorda Biomedicine team on bispecific antibody IND work
The collaboration covers preclinical pharmacology studies and clinical supply to support planned IND filings in China and the United States.
Read More
